New Jersey Woman Triumphs Over Glioblastoma with Innovative Cell Therapy

New Jersey Woman Triumphs Over Glioblastoma with Innovative Cell Therapy

A New Jersey woman has experienced a remarkable turnaround in her battle against brain cancer, thanks to a groundbreaking treatment. Pamela Goldberger, age 65, was diagnosed with glioblastoma in 2023, a type of brain cancer notorious for its aggressive nature and low survival rate.

A Life-Changing Diagnosis

Goldberger’s journey began with seemingly innocuous symptoms that escalated into a life-altering diagnosis. Initially, she only noticed a significant episode of nausea. However, during a routine dinner, she unexpectedly switched the use of her fork and knife. This alarming incident prompted her to seek medical attention.

Upon visiting the emergency room, she underwent several neurological tests, including MRIs and CAT scans. These diagnostic procedures revealed a brain tumor, leading to a devastating realization.

Confronting the Unknown

“It’s pretty devastating news to hear,” Goldberger reflected on her diagnosis. “I didn’t know what I thought was happening, but that wasn’t it. Our world just stopped.”

At that moment, the gravity of her situation struck her profoundly. The thought of not witnessing her grandchildren grow up weighed heavily on her heart.

Exploring Treatment Options

Goldberger was quickly admitted to the hospital, where she prepared for brain surgery. Conventional treatment for glioblastoma generally involves surgical intervention; however, the head of neurosurgery at Cooper University Hospital presented her with an alternative route.

He suggested that she consider joining a clinical trial focused on dendritic cell therapy tailored for glioblastoma patients, and she embraced this opportunity with hope.

Combination of Therapies

Following her surgery, Goldberger underwent a rigorous six-week regimen of chemotherapy and radiation therapy, which was later supplemented by the investigational cell therapy. This was followed by an additional year of maintenance chemotherapy.

While the recovery process was gradual, Goldberger began to regain her strength after completing the oral chemotherapy.

Beating the Odds

Now, two and a half years post-diagnosis, Goldberger is enjoying life in ways she had once feared would be impossible. She actively participates in tennis matches several times each week, a testament to her renewed vitality.

Understanding Glioblastoma Treatment

Dr. Joseph Georges, a neurosurgeon at Banner University Hospital in Phoenix, provided key insights into glioblastoma. He noted that survival rates and treatment efficacy have remained stagnant for the past two decades.

“It’s a highly mutated tumor, and each patient has distinct cell populations,” he explained. “The tumor is skilled at evading the body’s immune responses.”

The innovative dendritic cell therapy constructs a personalized vaccine derived from the patient’s tumor, harvested during surgery. This approach primes the immune system to effectively target and destroy the malignant cells.

The Clinical Trial Experience

This transformative therapy was administered to a group of 16 patients, ages ranging from 47 to 73, who were newly diagnosed with glioblastoma, including Goldberger herself. After undergoing the initial chemotherapy and radiation, participants received a series of injections every two weeks, complemented by weekly administration of a pegylated interferon medication.

Initial results from the phase one clinical trial were promising, indicating improved immune system responses and survival rates. Furthermore, the treatment exhibited a favorable safety profile with minimal side effects, even at higher doses.

Disappearance of Tumors

Dr. Georges expressed optimism about the results. “At best, we hope to keep it stable and hope that we don’t see it grow,” he said. “However, we are actually observing tumors disappear on MRIs, something unprecedented for glioblastoma.”

Goldberger’s experience epitomizes the potential of emerging treatments in overcoming this formidable disease.

Living a Full Life

Though she continues to have regular check-ups with her medical team, Goldberger reports feeling great. She relishes the opportunity to share precious moments with her grandchildren, play tennis, enjoy lunch with friends, and travel.

“I’m living my best life right now, unrestricted by anything,” she shared with enthusiasm.

Encouragement for Others

Goldberger offers valuable advice for others battling glioblastoma. She encourages patients to explore clinical trial opportunities and commit fully to their healing journeys.

“I was a diligent patient, following all of my doctors’ recommendations,” she stated. “I prioritized daily walks, maintained a healthy diet, and ensured adequate sleep.”

Additionally, she emphasizes the importance of surrounding oneself with positivity and supportive loved ones during the recovery process.

A Collaborative Effort

Dr. Georges concurs, encouraging glioblastoma patients to investigate available clinical trials that might offer new hope.

As of July 22, Diakonos Oncology announced the commencement of a phase two clinical trial for DOC1021. This new phase will be conducted at 20 sites nationwide, providing further opportunities for patients in need.

The journey taken by Goldberger and the advancements in glioblastoma research symbolize hope in the ongoing battle against this aggressive form of cancer.